Fri, April 15, 2011
Thu, April 14, 2011
Wed, April 13, 2011
Tue, April 12, 2011
Mon, April 11, 2011
Sun, April 10, 2011
Sat, April 9, 2011
Fri, April 8, 2011
Thu, April 7, 2011
[ Thu, Apr 07th 2011 ]: Market Wire
Volunteering Does a Body Good
Wed, April 6, 2011
Tue, April 5, 2011
Mon, April 4, 2011
Sun, April 3, 2011
Sat, April 2, 2011
Fri, April 1, 2011
Thu, March 31, 2011
Wed, March 30, 2011
Tue, March 29, 2011
Mon, March 28, 2011
Sun, March 27, 2011
Fri, March 25, 2011
Thu, March 24, 2011

DARA Biosciences, Inc. to Present at Taglich Brothers 8th Annual Small Cap Equity Conference


  Copy link into your clipboard //health-fitness.news-articles.net/content/2011/ .. hers-8th-annual-small-cap-equity-conference.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

NEW YORK, NY--(Marketwire - April 5, 2011) - [ Taglich Brothers, Inc. ] is pleased to announce that Richard Franco, President & CEO of [ DARA BioSciences, Inc ]. (NASDAQ: [ DARA ]) will be presenting at our 8th Annual Small Cap Equity Conference May 3rd, 2011. The Conference will take place at the New York Athletic Club, New York City. To request additional information or to [ register ], contact [ Taglich Brothers ] at 212-779-2971 or visit [ www.taglich.com ].

About Taglich Brothers

[ Taglich Brothers, Inc ]. is a full-service broker dealer focused exclusively on microcap companies. The Company defines the microcap segment of the equity market as companies with less than $250 million in market capitalization. Taglich Brothers currently offers institutional and retail brokerage services, investment banking and comprehensive research coverage to the investment community.

About DARA BioSciences, Inc.

[ DARA BioSciences, Inc. ] is a North Carolina based biopharmaceutical development company that acquires promising therapeutic candidates and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. Presently DARA has two drug candidates with cleared IND (Investigational New Drug) Applications from the United States FDA advancing through clinical development: 1. KRN5500 for the treatment of neuropathic pain; and 2. DB959 for the treatment of type 2 diabetes. In addition, the Company has a pipeline of diverse drug candidates at various stages of development, with 88 US and foreign granted patents and 60 pending applications. DARA owns CPT-1 inhibitors intended for topical application for patients with psoriasis, a library of DDPIV inhibitors and a diverse library of approximately 1800 PPAR agonists of various molecular modalities.


Publication Contributing Sources